Kyowa Kirin, Inc.
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1949-01-01
- Employees
- 7.1K
- Market Cap
- $12B
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02312687
- Locations
- 🇺🇸
Houston Methodist Reasearch Institute, Houston, Texas, United States
🇺🇸Indiana University Hospital, Indianapolis, Indiana, United States
🇺🇸University California San Francisco Hospital, San Francisco, California, United States
Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)
- Conditions
- Interventions
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT02304367
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Duke University, Durham, North Carolina, United States
Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT02301130
- Locations
- 🇺🇸
Georgia Cancer Center, Augusta, Georgia, United States
🇺🇸UCLA Hematology & Oncology Clinic, Los Angeles, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT02181699
- Locations
- 🇬🇧
University of Sussex, Royal Sussex County Hospital, Brighton, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧NIHR/Wellcome UCLH Clinical Research Facility University College Hospital London, London, United Kingdom
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT02163577
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇫🇷Bicetre Hospital, Le Kremlin- Bicetre, France
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 372
- Registration Number
- NCT01728805
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
- Conditions
- Interventions
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT01626664
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇫🇷Hospital Necker, Paris, France
A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Registration Number
- NCT00955045
- Locations
- 🇺🇸
48 Centers in the US and 4 in Canada, Princeton, New Jersey, United States
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
- Conditions
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT00575562
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
- Conditions
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 325
- Registration Number
- NCT00456794
- Locations
- 🇺🇸
Contact Kyowa Pharmaceutical, Inc., Princeton, New Jersey, United States